European Medicines Agency must take account of cardiovascular harm associated with degludec insulinBMJ 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f3731 (Published 11 June 2013) Cite this as: BMJ 2013;346:f3731
- Thomas A Schmidt, associate clinical research professor1,
- Clifford J Rosen, professor of medicine2,
- John S Yudkin, emeritus professor of medicine3
- 1Holbaek University Hospital, 4300 Holbaek, Denmark
- 2Maine Medical Center Research Institute, Scarborough, ME, USA
- 3University College London, London, UK
The way we manage diabetes is bad medicine and, with the increasing use of analogue insulin, type 2 diabetes is pharma’s lottery win.1 Degludec insulin (Tresiba), Novo Nordisk’s novel analogue, may be viewed in this context. Our concerns about its marketing led us to submit a letter to the European Medicines Agency (EMA) (available at: www.bmj.com/content/346/bmj.f2695/rr/648949).
The EMA approved degludec …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial